In March, Harbour BioMed, a global biopharmaceutical company collaborated with AstraZeneca to discover and develop next-generation multi-specific antibodies for immunology, oncology and beyond. The strategic collaboration included an option to license multiple programs utilizing Harbour BioMed's proprietary Harbour Mice fully human antibody technology platform in multiple therapeutic areas and a $105 million equity investment by AstraZeneca in Harbour BioMed.